This federal Project Grant award, identified as R01AI187556, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant totaling $749,417 was provided to President and Fellows of Harvard College, also known as Harvard University, to support research focused on the development of novel antibiotics targeting the lipoprotein transport system in Gram-negative bacteria.
The key objectives of this research project include diversifying and improving the modular platform for synthesizing candidate antibiotics with enhanced potencies against multidrug-resistant Escherichia coli and Klebsiella pneumoniae. Additionally, the research aims to deepen the understanding of the mechanism of action of these antibiotics by using cryo-electron microscopy imaging to visualize the molecules bound to their target, the LolCD2E lipoprotein transport machinery. This information will inform the structure-based design of future antibiotic candidates. The award period runs from November 20, 2024, to October 31, 2029.
Generated 1/28/25, 10:17 AM